Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

[Impaired immunity: risk groups and consequences for general practice].

Opstelten W, Bijlsma JW, Gelinck LB, Hielkema CM, Verheij TJ, van Eden W.

Ned Tijdschr Geneeskd. 2016;160:A9752. Dutch.

PMID:
27299487
2.

Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.

Rokx C, Gras L, van de Vijver D, Verbon A, Rijnders B; ATHENA National Observational Cohort Study..

HIV Med. 2016 Sep;17(8):571-80. doi: 10.1111/hiv.12355. Epub 2016 Feb 4.

PMID:
26842457
3.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study..

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.

PMID:
26762990
4.

Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort.

Op de Coul EL, van Sighem A, Brinkman K, van Benthem BH, van der Ende ME, Geerlings S, Reiss P; ATHENA National Observational HIV Cohort..

BMJ Open. 2016 Jan 4;6(1):e009688. doi: 10.1136/bmjopen-2015-009688.

PMID:
26729389
5.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration..

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

PMID:
26423376
6.

Follow-up of Contacts of Middle East Respiratory Syndrome Coronavirus-Infected Returning Travelers, the Netherlands, 2014.

Mollers M, Jonges M, Pas SD, van der Eijk AA, Dirksen K, Jansen C, Gelinck LB, Leyten EM, Thurkow I, Groeneveld PH, van Gageldonk-Lafeber AB, Koopmans MP, Timen A; MERS-CoV Outbreak Investigation Team of the Netherlands..

Emerg Infect Dis. 2015 Sep;21(9):1667-9. doi: 10.3201/eid2109.150560.

PMID:
26291986
7.

Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group..

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.

PMID:
25763785
8.

Diminished impact of ethnicity as a risk factor for chronic kidney disease in the current HIV treatment era.

Schoffelen AF, Smit C, van Lelyveld SF, Vogt L, Bauer MP, Reiss P, Hoepelman AI, Barth RE; ATHENA National Observational HIV Cohort..

J Infect Dis. 2015 Jul 15;212(2):264-74. doi: 10.1093/infdis/jiv026. Epub 2015 Jan 18.

PMID:
25601941
9.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration., Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

PMID:
25567330
10.

Changes in HIV RNA and CD4 cell count after acute HCV infection in chronically HIV-infected individuals.

Gras L, de Wolf F, Smit C, Prins M, van der Meer JT, Vanhommerig JW, Zwinderman AH, Schinkel J, Geskus RB; ATHENA national observational cohort and the MOSAIC study..

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):536-42. doi: 10.1097/QAI.0000000000000514.

PMID:
25559595
11.

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group..

Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.

PMID:
25042234
12.

[Influenza vaccination in immunocompromised patients].

Klinkenberg RE, Gelinck LB.

Ned Tijdschr Geneeskd. 2014;158:A7574. Review. Dutch.

PMID:
24988164
13.

Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study.

Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group..

BMC Nephrol. 2014 Mar 25;15:51. doi: 10.1186/1471-2369-15-51.

PMID:
24666792
14.

Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.

Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group..

BMC Infect Dis. 2013 Oct 9;13:471. doi: 10.1186/1471-2334-13-471.

PMID:
24106926
15.

Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The Netherlands.

Smit M, Smit C, Geerlings S, Gras L, Brinkman K, Hallett TB, de Wolf F; Athena Observational Cohort..

PLoS One. 2013 Sep 30;8(9):e76071. doi: 10.1371/journal.pone.0076071. eCollection 2013 Sep 30.

PMID:
24098764
16.

Associations between immune depression and cardiovascular events in HIV infection.

Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; D:A:D Study Group..

AIDS. 2013 Nov 13;27(17):2735-48. doi: 10.1097/01.aids.0000432457.91228.f3.

PMID:
23842128
17.

Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM?

Gras L, Geskus RB, Jurriaans S, Bakker M, van Sighem A, Bezemer D, Fraser C, Prins JM, Berkhout B, de Wolf F; ATHENA National Observational Cohort..

PLoS One. 2013 May 27;8(5):e64437. doi: 10.1371/journal.pone.0064437. Print 2013.

PMID:
23724048
18.

Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.

Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium.; INSIGHT.; Swiss HIV Cohort Study..

Clin Infect Dis. 2013 Jul;57(1):112-21. doi: 10.1093/cid/cit196. Epub 2013 Mar 26.

PMID:
23532479
19.

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group..

J Infect Dis. 2013 May 1;207(9):1359-69. doi: 10.1093/infdis/jit043. Epub 2013 Feb 4.

PMID:
23382571
20.

Lower incidence of Pneumocystis jirovecii pneumonia among Africans in the Netherlands host or environmental factors?

Schoffelen AF, van Lelyveld SF, Barth RE, Gras L, de Wolf F, Netea MG, Hoepelman AI; ATHENA national observational cohort study..

AIDS. 2013 Apr 24;27(7):1179-84. doi: 10.1097/QAD.0b013e32835e2c90.

PMID:
23276810

Supplemental Content

Loading ...
Support Center